Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 3/20 | 0.68 |
| ▸ | MAPT | P10636 | 8/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.60 |
| ▸ | TSHR | P16473 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 3/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.60 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | MAOB | P27338 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | STAT3 | P40763 | 4/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | FTO | Q9C0B1 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | RECQL | P46063 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29366938 | 1.00 | MAOA (0.68) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL30361371 | 1.00 | MAOA (0.68) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL142033 | 0.95 | ALDH1A1 (0.69) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL11147739 | 0.85 | ALDH1A1 (0.70) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL8505898 | 0.85 | ALDH1A1 (0.58) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL13880670 | 0.84 | ELANE (0.50) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| SCHEMBL13881115 | 0.84 | ELANE (0.50) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| Anthrarufin SCHEMBL187843 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| Anthrarufin SCHEMBL29363946 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1TDP1MAPK1 | |
| Anthrarufin SCHEMBL29874705 | 0.82 | MAOA (1.00) | MAOAMAPTALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015167567-A1 | STAT3 INHIBITORS FOR TREATMENT OF HYPERGLYCEMIA AND IMPAIRED SPATIAL VISION | CHARLESSON LLC (US) | 2015-11-05 | — | — | WO | claimed |
| EP-4376960-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | The Johns Hopkins University (US) | 2024-06-05 | — | — | EP | disclosed |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | UNIVERSITY OF ROCHESTER | 2023-06-22 | — | — | US | disclosed |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | UNIVERSITY OF ROCHESTER | 2023-06-22 | — | — | US | disclosed |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | UNIVERSITY OF ROCHESTER | 2023-05-04 | — | — | US | disclosed |
| WO-2023010141-A1 | CONCURRENT TARGETING OF ONCOGENIC PATHWAYS TO ENHANCE CHEMOTHERAPY AND IMMUNOTHERAPY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-02-02 | — | — | WO | disclosed |
| EP-2968139-B1 | MICROEMULSION TOPICAL DELIVERY PLATFORM | EYECRO LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| EP-2968139-B1 | MICROEMULSION TOPICAL DELIVERY PLATFORM | EYECRO LLC (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140275263-A1 | Microemulsion Topical Delivery Platform | EyeCRO, LLC (US) | 2014-09-18 | — | — | US | disclosed |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | CHARLESSON, LLC (US) | 2012-03-08 | — | — | US | disclosed |
| US-8058316-B2 | STAT3 inhibiting compositions and methods | CHARLESSON, LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058316-B2 | STAT3 inhibiting compositions and methods | CHARLESSON, LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-8058316-B2 | STAT3 inhibiting compositions and methods | CHARLESSON, LLC (US) | 2011-11-15 | — | — | US | disclosed |
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | CHARLESSON, LLC (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | CHARLESSON, LLC (US) | 2011-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077306-A1 | STAT3 INHIBITING COMPOSITIONS AND METHODS | STAT3, STAT1, STAT5B | MAOA 4674/4885MAPT 669/4885ALDH1A1 1563/4885 |
| US-20230133695-A1 | METHODS AND COMPOSITIONS FOR REJUVENATING CNS GLIAL POPULATIONS BY SUPPRESION OF TRANSCRIPTION FACTORS | IKZF3, IKZF1, CXXC4 | MAOA 3722/4885MAPT 3029/4885ALDH1A1 3617/4885 |
| US-20230190961-A1 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | TEAD2, MYT1, TEAD1 | MAOA 3724/4885MAPT 1360/4885ALDH1A1 3276/4885 |
| US-20120059067-A1 | 1-ACETYL-5-HYDROXYANTHRACENE-9,10-DIONE FOR TREATMENT OF RETINAL DISEASE | ACAT1, ACAT2, LCLAT1 | MAOA 1444/4885MAPT 65/4885ALDH1A1 55/4885 |
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | MYT1, STAT3, MYC | MAOA 4555/4885MAPT 2744/4885ALDH1A1 3434/4885 |
| US-20140275263-A1 | Microemulsion Topical Delivery Platform | LIPA, MITF, CETP | MAOA 727/4885MAPT 1261/4885ALDH1A1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.